brain tumors (glioblastoma multiforme, or GBM) that do
not respond to traditional chemoradiation treatment may
respond to Cotara®.
is a monoclonal antibody that targets the DNA of cancer
cells and carries a radioactive isotope.
is delivered through a method called convection enhanced
delivery (CED), which uses a catheter to bypass the blood-brain
barrier and target the specific tumor site in the brain.
of the University of Pennsylvania (HUP) is one
of four sites participating in the clinical trail of
(PHILADELPHIA) – Physicians initially diagnosed
Phil Marfuta, 28, with tension
headaches, which seemed reasonable
to him since he is a busy graduate student studying physics at
Princeton University. However, as the days went on his headaches
did not subside, and when a CT
scan and an MRI revealed two tumors,
Phil underwent emergency surgery at the Hospital of the
University of Pennsylvania.
One of Phil’s tumors was a grade IV glioblastoma
multiforme (GBM), which is the most aggressive form of primary brain tumor.
Typically once diagnosed, the median survival time for a patient
with a GBM is 12 months.
“That kind of news is the kind you don’t want to have
to call your family and tell them about,” says Phil.
Phil’s tumors had stopped responding to traditional chemoradiation treatment and to a clinical trial that added an immune
modulator to his therapy. That’s when he learned of the Cotara® trial.
About Cotara® and the Clinical Trial
Cotara is delivered through a method called convection
enhanced delivery (CED).
Click on thumbnail
to view full-size image
Cotara is a monoclonal antibody that targets the DNA of cancer cells and carries a radioactive
isotope to them, literally destroying
the cancer cells from the inside out. GBMs are complicated
to treat because filaments of malignant
cells spread out like fingers
from the tumor and take root deep in the surrounding tissue, making
it difficult to remove them without damaging healthy brain cells. This
approach targets the cancer cells, while sparing healthy tissue
in the brain.
In November, 2006, Phil was treated in this clinical trial of
Cotara. “It involved
so compared to a craniotomy,
that sounded quite nice,” recalls Phil. To-date, Phil’s
GBM has been stabilized
HUP is one of four sites participating in the clinical trail of
Cotara, a biological “guided missile” for the treatment
of GBM, a deadly form of brain cancer that is newly diagnosed in
more than 10,000 Americans each year.
Phil feels very strongly about the importance of participating
in clinical trials and has even posted an account of his experience
on the Young Adults Surviving Glioblastoma’s Web site.
“I’m very passionate about science and I really enjoy
finding things out and experimenting. By participating in
this trial, somehow I feel like I’ve actually done something
tangible to help other people who are basically going through the
same thing that I am going through. That’s a small
thing, but to me, it’s a very active step and it makes me
feel good that there’s a contribution that I’ve made,” says
Phil. “I sincerely wish that people would take that
step and participate in these trials.”
A Different Approach for Treating Brain Tumors
“Based on the scientific rationale for Cotara, coupled with
some positive but preliminary indications from previous trials,
we believe it is important to study this approach as a new option
for this deadly disease,” says Kevin D. Judy, MD,
Associate Professor, Department
of Neurosurgery at Penn.
“One challenge in treating brain tumors is the difficulty
of delivering therapeutic agents to the brain through the blood-brain
barrier (BBB) – the physical shield that serves to protect
the brain and central
nervous system from potentially dangerous
or infectious agents,” says Myrna R. Rosenfeld, MD,
PhD, Chief of Penn’s Division
of Neuro-Oncology. Cotara
is delivered through a method called convection
enhanced delivery (CED), which uses a catheter to bypass the BBB and target the specific
tumor site in the brain. “This method enables us to
treat GBMs with local therapy that does not have side effects elsewhere
in the body,” says Robert Lustig, MD, Clinical
Associate Professor of Radiation
Oncology at Penn.
The Objective of the Clinical Trial
2 clinical trial is designed to evaluate a single Cotara
infusion in patients with a first or second recurrence of GBM. The
primary endpoints of the trial are to confirm safety and determine
median survival time and median time to progression in patients
treated with Cotara. Cotara has been granted orphan
drug status and fast
track designation by the U.S. Food
and Drug Administration for the treatment of GBM.
Inc., developers of Cotara, is working
with the New Approaches to Brain
Tumor Therapy (NABTT) to conduct
the trial at Penn, Wake Forest University, Emory
the University of Alabama at Birmingham.
Editor's Notes: Dr. Judy, Dr. Rosenfeld, and
Dr. Lustig have no financial interest in Peregrine Pharmaceuticals,
For additional information about the trial at Penn, call (215)
For information regarding the other sites, call (800) 694-5334
or visit www.clinicaltrials.gov/ct/show/NCT00128635?order=1
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.